Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Danaher Co. (NYSE:DHR - Free Report) by 2.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 306,686 shares of the conglomerate's stock after purchasing an additional 8,143 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Danaher were worth $70,949,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Banco Santander S.A. bought a new position in Danaher during the 3rd quarter valued at about $683,000. First Citizens Bank & Trust Co. lifted its stake in Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate's stock valued at $6,156,000 after acquiring an additional 149 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Danaher by 48.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate's stock valued at $68,707,000 after acquiring an additional 96,395 shares during the period. Parkside Financial Bank & Trust lifted its stake in shares of Danaher by 4.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate's stock worth $764,000 after purchasing an additional 142 shares during the period. Finally, Keybank National Association OH lifted its stake in shares of Danaher by 0.5% in the 3rd quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate's stock worth $137,238,000 after purchasing an additional 2,567 shares during the period. Institutional investors own 79.05% of the company's stock.
Danaher Stock Up 0.3 %
Shares of DHR stock traded up $0.69 on Tuesday, hitting $240.35. The stock had a trading volume of 3,225,223 shares, compared to its average volume of 2,703,507. The business has a 50 day moving average price of $249.42 and a 200 day moving average price of $229.79. Danaher Co. has a one year low of $182.09 and a one year high of $259.00. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The company has a market cap of $177.99 billion, a PE ratio of 37.61, a P/E/G ratio of 3.65 and a beta of 0.83.
Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The company had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. During the same quarter in the previous year, the firm earned $2.87 earnings per share. The firm's quarterly revenue was down 10.2% compared to the same quarter last year. Research analysts anticipate that Danaher Co. will post 7.62 earnings per share for the current fiscal year.
Danaher Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. This is a positive change from Danaher's previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher's payout ratio is presently 16.90%.
Insider Transactions at Danaher
In related news, SVP Daniel Raskas sold 23,757 shares of the company's stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, SVP Daniel Raskas sold 23,757 shares of the company's stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Teri List sold 3,289 shares of the company's stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,957 shares of company stock worth $8,265,802. Insiders own 10.90% of the company's stock.
Wall Street Analyst Weigh In
DHR has been the topic of a number of recent analyst reports. Citigroup raised their target price on shares of Danaher from $255.00 to $280.00 and gave the stock a "buy" rating in a research note on Wednesday, January 31st. Barclays raised their target price on shares of Danaher from $240.00 to $260.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 10th. JPMorgan Chase & Co. raised their target price on shares of Danaher from $250.00 to $270.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 20th. StockNews.com cut shares of Danaher from a "buy" rating to a "hold" rating in a research note on Wednesday, January 31st. Finally, KeyCorp increased their price objective on shares of Danaher from $260.00 to $290.00 and gave the company an "overweight" rating in a report on Thursday, February 1st. Seven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $267.43.
Read Our Latest Report on DHR
Danaher Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
